From MSO asset purchases to physician equity rollovers and SBA 7(a) financing — a practical guide to deal structures for dermatology practices generating $1M–$5M in revenue.
Dermatology practices are among the most sought-after acquisition targets in lower middle market healthcare M&A. Their dual revenue model — combining insurance-reimbursed medical dermatology with high-margin cash-pay cosmetic services like Botox, fillers, and laser treatments — creates resilient cash flows that appeal to both private equity roll-up platforms and independent physician buyers. However, deal structuring in dermatology is more complex than a standard business acquisition. Corporate practice of medicine (CPOM) laws in many states prohibit non-physician entities from directly owning a medical practice, requiring specialized structures like Management Services Organizations (MSOs). Additionally, physician retention risk, payer contract assignability, malpractice tail coverage, and earnout mechanics tied to provider performance all shape how deals are built and negotiated. EBITDA multiples for dermatology practices typically range from 4x to 7x, with premium valuations awarded to practices with diversified provider teams, strong cosmetic revenue mix, and clean billing histories. Understanding which deal structure aligns with your financing source, risk tolerance, and post-close goals is the first step toward a successful transaction.
Find Dermatology Practice Businesses For SaleAsset Purchase with MSO Structure
The buyer acquires the tangible and intangible assets of the dermatology practice — including equipment, patient lists, goodwill, and contracts — while a physician-owned professional corporation (PC) or professional association (PA) retains ownership of the licensed medical entity. A separate Management Services Organization (MSO) owned by the buyer provides administrative, billing, staffing, and operational services to the physician PC under a long-term management agreement. This bifurcated structure is designed to comply with corporate practice of medicine laws in states like California, Texas, and New York.
Pros
Cons
Best for: Private equity-backed dermatology roll-up platforms and non-physician buyers acquiring practices in CPOM-restricted states, or any buyer seeking to minimize inherited liability exposure while capturing the full economic upside of the practice.
Stock Purchase with Physician Equity Rollover
The buyer acquires the ownership interest (stock or membership units) in the existing practice entity directly from the physician seller. A portion of the purchase price — typically 10–20% — is retained by the selling physician as rolled equity in the acquiring platform or a newly formed holding company. This aligns the seller's post-close incentives with the buyer's growth objectives and is common in private equity dermatology platform transactions where the selling physician continues as a clinical leader.
Pros
Cons
Best for: Private equity dermatology platforms acquiring a practice where the founding physician wants to retain a stake and remain clinically active, and where speed of close and payer contract continuity are priorities.
SBA 7(a) Loan with Seller Note
An independent physician buyer or small medical group finances the acquisition using an SBA 7(a) loan — typically covering 75–80% of the purchase price up to $5M — combined with a seller note representing 10–15% of the purchase price, with the buyer contributing 10% equity as a down payment. The seller note is typically subordinated to the SBA loan, carries a 6–8% interest rate, and is repaid over 3–5 years. This structure is well-suited for dermatology practices meeting SBA eligibility standards and is the primary path for non-PE individual buyers.
Pros
Cons
Best for: Independent physicians, small physician groups, or entrepreneurial buyers acquiring a single dermatology practice from a retiring dermatologist, particularly where the practice has clean financials, a diversified payer mix, and EBITDA above $500K.
Earnout with Base Purchase Price
A portion of the total purchase price — typically 15–25% — is deferred and paid to the seller based on the practice achieving specified EBITDA or revenue milestones over a 2–3 year post-close period. The base purchase price is paid at closing via cash, SBA financing, or PE equity, while the earnout provides downside protection for the buyer if key physician retention, payer reimbursement, or patient volume targets are not met. Common earnout triggers include annual EBITDA thresholds, cosmetic revenue retention benchmarks, and founding physician clinical hours.
Pros
Cons
Best for: Acquisitions where the selling dermatologist is staying on for a 12–36 month transition period and a material portion of practice value — particularly cosmetic revenue or a growing ancillary service line — is tied to the founder's continued clinical presence.
Retiring Solo Dermatologist — SBA 7(a) Purchase by Independent Physician Buyer
$3,200,000
SBA 7(a) loan: $2,560,000 (80%) | Seller note: $480,000 (15%) | Buyer equity injection: $160,000 (5% — SBA minimum with seller note in place)
Practice generates $780K EBITDA on $2.4M revenue with 60% medical dermatology and 40% cosmetic revenue. SBA loan structured over 10 years at prevailing SBA rate (estimated 9.5–10.5%). Seller note at 6.5% interest, interest-only during SBA standby period (approximately 24 months), then principal and interest for remaining 3 years. Seller provides 18-month clinical transition, introducing patients to the acquiring physician. Asset purchase structure used to avoid assuming legacy malpractice tail liability. Seller funds tail coverage for claims-made malpractice policy as a closing condition. No earnout given seller's full exit intent.
Private Equity Roll-Up Platform Acquiring Multi-Physician Practice with Physician Equity Rollover
$8,500,000
PE cash at close: $6,800,000 (80%) | Physician equity rollover: $1,275,000 (15%) | Earnout tied to 2-year EBITDA performance: $425,000 (5% — maximum earnout potential)
Three-dermatologist practice generating $1.3M EBITDA on $4.2M revenue. Structured as a stock purchase into PE platform's affiliated MSO holding structure with physician PC retained for CPOM compliance. Founding physician rolls 15% as equity in the platform's next fund vehicle, with projected liquidity at platform exit in 4–6 years. Earnout of up to $425,000 paid in two tranches at months 12 and 24 if combined EBITDA exceeds $1.4M and $1.55M respectively. Founding physician signs 3-year employment agreement at market compensation plus RVU bonus. Non-compete covers 25-mile radius for 3 years post-employment termination. PE platform assumes lease with 7 years remaining and landlord assignment consent obtained at closing.
Mid-Market Physician Group Acquiring Cosmetic-Heavy Practice with MSO Structure and Seller Note
$5,100,000
Buyer cash at close (conventional financing): $3,570,000 (70%) | Seller note: $1,020,000 (20%) | Earnout based on cosmetic revenue retention: $510,000 (10%)
Practice generates $980K EBITDA on $3.1M revenue with 55% cosmetic revenue (Botox, laser, chemical peels) and 45% medical dermatology. MSO asset purchase structure implemented due to California CPOM restrictions. Seller note at 7% interest over 5 years, with 12-month interest-only period. Earnout payable at month 24 if cosmetic revenue equals or exceeds $1.5M — payable in cash from operating cash flow, not buyer equity. Founding physician remains as Medical Director for 24 months at $280,000 annual compensation, maintaining cosmetic patient relationships during transition. Payer contracts re-credentialed under new physician PC entity; billing holdback of $75,000 retained in escrow for 90 days to cover any disputed claims from pre-close billing cycles.
Find Dermatology Practice Businesses For Sale
Pre-screened targets ready for your deal structure — free to join.
A Management Services Organization (MSO) is a business entity that provides non-clinical services — such as billing, staffing, marketing, facility management, and administrative operations — to a physician-owned professional corporation (PC) under a long-term management agreement. This structure is required in states with corporate practice of medicine (CPOM) laws, which prohibit non-physician entities from directly owning or controlling a licensed medical practice. In dermatology acquisitions involving private equity buyers or non-physician investors, the MSO captures the economic value of the practice while the physician PC retains technical ownership of the medical license and clinical operations. States with strict CPOM enforcement including California, Texas, and New York require MSO structures for non-physician acquirers. Always retain a healthcare M&A attorney to assess CPOM requirements in your specific state before structuring any dermatology deal.
Dermatology practices in the $1M–$5M revenue range typically trade at 4x to 7x EBITDA. Practices at the lower end of the range tend to be solo-physician operations with heavy Medicare dependency, aging equipment, or declining patient volume. Practices commanding 6x–7x multiples typically have three or more licensed providers, strong cosmetic revenue (30–50% of total revenue), diversified payer mix with less than 40% Medicare concentration, modern EMR infrastructure, and a lease with at least 5 years remaining. Private equity roll-up platforms often pay premium multiples for practices that provide geographic density or add a new market to an existing portfolio, and may offer higher headline prices offset by earnout risk and equity rollover rather than all-cash at close.
Yes. Dermatology practices are SBA-eligible businesses, and SBA 7(a) loans are one of the most common financing tools for independent physician buyers acquiring practices in the $1M–$5M revenue range. The SBA 7(a) program allows loans up to $5M with 10-year repayment terms and competitive interest rates. Buyers typically contribute 10% equity at closing and may combine the SBA loan with a seller note of 10–15% to reduce the cash required. SBA lenders will require 3 years of practice financials, a business plan, physician employment agreements, payer contract documentation, and evidence of clean malpractice history. Note that SBA financing is only available to owner-operator buyers — private equity firms and passive investors are not eligible. Work with an SBA lender that has specific experience financing medical practice acquisitions, as general commercial banks often misunderstand healthcare-specific underwriting requirements.
Earnouts in dermatology acquisitions typically represent 10–25% of total deal value and are triggered over a 2–3 year post-close measurement period. The most defensible earnout structures are tied to EBITDA rather than gross revenue, with clearly defined expense allocation rules to prevent buyer manipulation of the cost structure. For cosmetic-heavy practices, consider tying a portion of the earnout to cosmetic revenue retention as a percentage of pre-close run rate, since this is the component most at risk if the founding physician reduces their aesthetic patient engagement. All earnout agreements should include: a detailed accounting methodology, buyer obligations to maintain operational continuity (preventing the buyer from deliberately reducing revenue to avoid payment), a dispute resolution mechanism with an agreed-upon third-party accountant arbitrator, and a cap on total earnout liability. Sellers should push for quarterly reporting against milestones, not just annual review.
Payer contract treatment depends on the deal structure. In a stock purchase, existing contracts typically transfer to the buyer with the entity, though change-of-ownership notifications are usually required and some payers may trigger renegotiation or re-credentialing clauses. In an asset purchase or MSO restructuring, contracts generally do not automatically transfer — the new physician entity must apply for new provider numbers and re-credential with each payer, which can take 60–120 days and may temporarily disrupt billing. Medicare and Medicaid contracts require specific enrollment procedures and change-of-ownership notifications with CMS. To manage the gap, buyers often negotiate a billing and collections arrangement with the seller during the transition period — sometimes structured as a temporary management agreement — and build a receivables holdback into the closing escrow to cover disputed or delayed claims. Reviewing all payer contracts for assignment restrictions is a critical pre-LOI due diligence step.
Key-person risk is the most significant valuation discount factor in dermatology acquisitions. If a single physician generates 70–80% or more of practice revenue, buyers should take several protective steps. First, adjust the valuation downward — apply a 3–4x multiple to the physician-dependent revenue rather than the standard practice multiple. Second, structure a meaningful portion of the purchase price as an earnout tied to patient retention and provider continuity metrics over 24–36 months. Third, negotiate a physician employment agreement with a compensation structure that incentivizes the seller to actively transition patients to successor providers rather than simply clock out after the minimum transition period. Fourth, require the seller to introduce successor dermatologists or NP/PA providers pre-close if possible, establishing those providers as primary point-of-care for at least a segment of the patient base before the transaction closes. Finally, include a clawback provision in the purchase agreement if patient retention falls below an agreed threshold in the first 12 months post-close.
More Dermatology Practice Guides
More Deal Structure Guides
Find the right target, structure the deal, and close with confidence.
Create your free accountNo credit card required
For Buyers
For Sellers